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Abstract. Synthesis and characterization of the new cyclometalated
complex salts [Rh(ptpy)2(5.6-dimethyl-1,10-phenanthroline)]PF6 (1a)
[Rh(ptpy)2(2.9-dimethyl-4.7-diphenyl-1,10- phenanthroline)]PF6 (2a),
[Rh(ptpy)2(5-amino-1,10-phenanthroline)] PF6 (3a), and
[M(ptpy)2 (pyrazino-[2.3-f]-1,10-phenanthroline)]PF6 (M = Rh, 4a;
M = Ir, 4b), (ptpy = 2-(p-tolyl)pyridinato) are described. The molecular
Introduction
Since the discovery of the anti-cancer activity of cisplatin
(cis-diammine-dichlorido-platinum(II)) more than 50 years
ago, numerous transition metal complexes have been tested for
their cytostatic activities, both in vitro and in vivo. Among
those, cyclometallated iridium and rhodium complexes have
evolved as a major object of study in the last decade, as they
allow both therapeutic and diagnostic applications.,[1,2] This
“theranostic” approach is particularly useful with bis-cyclo-
metallated iridium(III) complexes of the type
“[M(C∧N)2(N∧N)]+”, as they show intense phosphorescence,
which also allows their use in light-emitting electrochemical
cells.[3] It was also shown that modifications of the cyclo-
metallating ligand “C∧N” and/or the ancillary ligand “N∧N”
allowed both fine-tuning of the anticancer and imaging proper-
ties.[4]
While the photophysical properties of the IrIII compounds
are superior to those of the corresponding RhIII complexes,[5]
and therefore make the iridium complexes more useful with
regard to diagnostic and phototherapeutic studies, this is not
the general case for the antiproliferative properties. For exam-
ple, while the iridium complex [Ir(ptpy)2(4,4-dinonyl-2,2-
bipy)]+ (ptpy = para-tolyl-pyridinato) was much more effec-
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structures of compounds 1b and 4a in the solid state were determined
by single-crystal X-ray diffraction. All these compounds and their al-
ready known Iridium counterparts 1b – 3b display significant cytotoxi-
city against human cancer cell lines MCF-7 (human breast adenocarci-
noma) and HT-29 (colon adenocarcinoma) with IC50 values in the low
micromolar range.
tive towards transfected HEK293T cells than its rhodium con-
gener,[6] the rhodium complexes [Rh(phquin)2(4,4-R2-2,2-
bipy)]+ (phquin = phenylquinolinato) performed much better
in MDA-MB-231 cells (R2 = diphenyl) or RAW264.7 cells
(R2 = dinonyl) than their iridium counterparts.,[7,8] Besides the
nature of the metal, the substituents on the cyclometallating
ligands as well as on the ancillary ligand have a great influence
on the cancerostatic performance of these complexes. For ex-
ample, we concentrated our cytostatic studies on the human
adenocarcinoma cell lines MCF-7 and HT-29, mostly using the
para-tolyl-pyridinato cyclometallating ligand and substituted
2,2-bipyridines as ancillary ligands (Scheme 1).
Scheme 1. Cyclometallated rhodium und iridium complexes with sub-
stituted 2,2-bipyridines as ancillary ligands studied by us earlier.
We found that the performance of bis-hydroxymethyl com-
plexes of series III was inferior compared to the other tested
structures with both metals and towards both cell lines, but
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Scheme 2. Synthesis of compounds 1a/b – 4a/b.
were still comparable to cisplatin (IC50 values ca. 10–12 μM
vs. 10–23 μM). Slightly better performance was shown by the
tert-butyl complexes IVd (IC50 values ca. 7μM towards HT-
29 and ca. 9 μM towards MCF-7 for both metals). In case
of 6,6-dimethyl-substituted complexes I the iridium complex
performed 15–18 times better than the rhodium complex, with
both compounds being more effective towards HT-29 by a fac-
tor of 2.5 to 3.5. The chlorido-substituted compounds II had a
very good performance towards HT-29 for both metals (IC50
values of ca. 0.5 μM), while they were less effective towards
MCF-7 by a factor of 2.5 to 5.5, with a slightly superior per-
formance of the iridium complex. The best results were ob-
tained with complexes carrying n-alkyl substituents in the 4,
4’-positions, showing no differences between the metals and
the two cell lines (all IC50 values 0.12–0.19 μM).[9]
Herein, we now report a systematic structure-activity (SAR)
study on isostructural bis-cyclometalated Rh and Ir complexes,
using the 1,10-phenanthroline ligand with substituents of dif-
fering steric demand and electronic properties.
Results and Discussion
The reactions of the chloride-bridged precursor complexes
[M(ptpy)2(μ-Cl)]2 (M = Rh, Ir) with substituted phenanthrol-
ines in a refluxing CH2Cl2/MeOH mixture followed by meta-
thetic exchange with PF6– for chloride yielded the title com-
pounds 1a–4a (M = Rh) and 1b–4b (M = Ir) (Scheme 2). The
analytical data of the chloro-substituted compounds 5a/b cor-
responds to the values we described previously.[10]
All compounds are obtained as yellow crystals in yields of
ca. 40% and were characterized by elemental analyses, mass
spectrometry, 1H NMR and 13C NMR spectroscopy. The irid-
ium complexes 1b – 3b have been reported before, prepared
by the same method and were obtained in yields of 50–
60%.[11–13] They had been prepared in the context of studies
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towards biological labeling reagents, particular as G-quadru-
plex-selective probes and STAT3 inhibitors. A rhodium com-
plex closely related to 2a with phenylpyridinato instead of the
tolylpyridinato cyclometallating ligands had also been reported
before and was shown to have strong anti-proliferative activity
against A2058 melanoma cells.[14] A phenylpyridinato analog
of the iridium pyrazino-phenanthroline complex 4b had origi-
nally been studied as potential luminescent nucleic acid inter-
calator,[15] but was recently also suggested for a potential use
in LEDs.[16]
Crystals of compounds 1b and 4a were studied by X-ray
structure analysis. orte representations of both compounds are
depicted in Figure 1 and Figure 2.
Figure 1. Molecular structure of the cation of 1b. Thermal ellipsoids
are at the 30% probability level.
Compound 1b crystallizes in the centrosymmetric space
group P21/n, compound 4a in the triclinic space group P1̄.
4a crystallizes with 1.5 CH2Cl2 molecules per formula unit,
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Table 1. Selected bond parameters /Å,° of 1b and 4a.
M–Nphen M–NC∧N M–CC∧N (N–M–N)phe (N–M–C)C∧N
1b 2.140(2), 2.144(2) 2.049(2), 2.052(2) 2.009(2), 2.014(2) 78.85(7) 80.35(8), 80.19(8
4a 2.150(4), 2.159(4) 2.040(5), 2.041(5) 1.9936(6), 1.933(6) 75.05(16) 81.1(2), 81.3(2)
Figure 2. Molecular structure of 4a. Thermal ellipsoids are at the 30%
probability level.
whereby the carbon atom of the “half” solvent molecule is
disordered over two positions (with the consequence that the
attached two hydrogen atoms had to be left out of the refine-
ment). In both compounds, the PF6 anions are involved in non-
classical hydrogen bonds with some aromatic C–H bonds. As
usual, both the ΔM and ΛM enantiomers are found in the crys-
tal, and the nitrogen atoms of the cyclometallating ligands are
in mutual trans configuration in both compounds. Also in both
compounds, the bond lengths from the metal to the phen-
anthroline nitrogen atoms are longer than those to the ptpy
nitrogen atoms and the N–M–C chelate angles are slightly
larger than the N–M–N chelate angle. Selected bond param-
eters around the central metal atoms are collected in Table 1.
Biological Activity
To estimate the impact of our compounds on cancerous
cells, the presented complexes were subjected to an MTT as-
say, measuring the metabolic activity of the treated cells which
allows for a correlation to cell viability. The human cell lines
HT-29 (colorectal adenocarcinoma) and MCF-7 (breast adeno-
carcinoma) served as test organisms in this study and the re-
sulting IC50 values are summarized in Table 2.
Table 2. Antiproliferative activities of the studied compounds.
Compound IC50 [μM] HT-29 IC50 [μM] MCF-7
1a 1.53 0.58 1.020.25
2a 0.510.11 0.470.07
3a 0.470.05 0.750.06
4a 1.660.08 1.57 0.36
1b 1.330.45 0.520.16
2b 0.480.26 0.430.14
3b 0.610.10 0.78 0.25
4b 1.760.27 1.440.41
5a [10] 0.50.1 1.00.3
5b [10] 0.20.1 0.3 0.1
Z. Anorg. Allg. Chem. 2020, 665–669 www.zaac.wiley-vch.de © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim667
Both tested cell lines were found to be susceptible towards
the tested complexes in the low micromolar or even in the
nanomolar concentration range. The most striking deviations
were observed for compounds with substituents at 5 and 6 po-
sition, i.e. compounds 1 and 4, which show an approximately
threefold lower activity against HT-29 (1a: 1.53 μM, 4a
1.66 μM) and MCF-7 (1a: 1.02 μM, 4a: 1.57 μM) cells com-
pared to the compounds without a functional substitution at
these positions. The remaining compounds of series 2 and 3
show IC50 values between 0.47 μM and 0.75 μM against both
cell lines.
Considering the error limits, no significant differences in
activity of individual compounds against the two tested cell
lines were observed (except for 1b, which was performing bet-
ter towards MCF-7 by about a factor of 2). All rhodium com-
pounds show the same activities as the corresponding iridium
complexes, except for the chloro-substituted compounds 5,
where the iridium compound performs better by a factor of ca.
3. Despite of the described minor differences in activity, the
presented complexes obviously represent highly active candi-
date compounds that can further be fine-tuned in future studies.
Conclusions
Five new bis-cyclometallated rhodium and iridium com-
plexes with differently substituted 1,10-phenanthroline ligands
were prepared in moderate yields (40–46%) and were studied
together with three other closely related complexes for their
proliferative activities. Despite of the differences in activity, it
can be stated that all complexes show a significantly higher
activity than the clinical drug cisplatin on both cell lines (IC50
for cisplatin: 10.4 μM for HT-29 and 23.1 μM for MCF-7). At
least with the phenanthroline ligands of this study, there seems
to be no drastic effect neither of the nature of the metal atom
nor the kind of substituents. However, introducing functional
substituents in 5 and 6 position of the phenanthroline moiety
caused a significant decrease in anti-cancer activity. Thus,
modulation of lipophilicity as well as functional modification
should rather be conducted in the remaining positions as the
antiproliferative activity seems to be less affected. An interest-
ing task for future studies might be the separation of the Λ,
Δ enantiomers and studying the effect of the chirality on the
proliferative activity.
Experimental Section
All manipulations were performed in an atmosphere of dry nitrogen
using conventional Schlenk techniques. 1,10-phenanthroline
ligands were purchased from Aldrich and used as received.
[{M(μ-Cl)(C∧N)2}2] (M = Rh, Ir) were prepared by adequately modi-
fied literature methods.[17] NMR spectra were usually recorded in
CD2Cl2 using a Jeol Eclipse 400 instrument operating at 400 MHz
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(1H) and 100 MHz (13C) respectively and also using Jeol Eclipse 270.
Chemical shifts are given in ppm, referenced to the solvent signals at
δ = 5.30 (1H) or 53.8 ppm (13C). Mass spectra were measured using a
Jeol Mstation JMS 700 spectrometer. Elemental analyses (C, H, N)
were performed by the Microanalytical Laboratory of the Department
of Chemistry, LMU Munich, using a Heraeus Elementar Vario EL in-
strument.
Crystals of 1b and 4a suitable for an X-ray diffraction study were
grown from CH2Cl2/CHCl3/hexane solutions. 1b was measured on a
Bruker d8 venture instrument, while 4a was examined on an
Oxford xcalibur2 instrument. The structures were solved with
Shelxt and refined with shelxl 2018/3, graphics were produced with
Ortep3 for windows, and tested for residual solvent with Platon,
all programs included in Wingx.[18] Details of the crystal data, data
collection, structure solution, and refinement parameters are summa-
rized in Table 3.
Table 3. Experimental details of the crystal structure determinations.
1b 4a
Empirical formula C38H32F6IrN4P C39.5H30Cl3F6N6PRh
Formula weight 881.84 942.92
Temperature /K 100(2) 100(2)
Crystal system monoclinic triclinic
Space group P21/n P1̄
Unit cell dimensions
a /Å 9.51000(4) 8.8154(5)
b /Å 13.8467(6) 13.0895(9)
c /Å 15.4480(11) 17.6440(10)
α /° 90 70.918(6)
β /° 97.6540(10) 80.957(4)
γ /° 90 85.968(5)
Volume /Å3 3321.2(2) 1899.8(2)
Z 4 2
Density (calcd.) /g·cm–3 1.764 1.648
Absorption coefficient / 4.138 0.772
mm–1
F(000) 1736 948
Crystal size /mm3 0.060.040.02 0.3480.108 0.09
Theta range for data col- 2.614 to 30.517 4.289 to 25.026
lection /°
Index ranges –13  h  13 –10  h  10
–19  k  19 –9  k  15
36  l  35 –19  l  20
Reflections collected 67573 10061
Independent reflections 10133 [R(int) = 6636 [R(int) =
0.0509] 0.0339]
Max. and min. trans- 0.7461 and 0.6879 1 and 0.93559
mission
Data / restraints / param- 10133 / 0 / 455 6636 / 1 / 516
eters
Goodness-of-fit on F2 1.048 1.045
Final R indices R1 = 0.0217, wR2 R1 = 0.0599, wR2 =
[I  2σ(I)] = 0.0450 0.1362
R indices (all data) R1 = 0.0291, wR2 R1 = 0.0825, wR2 =
= 0.0485 0.1590
Largest diff. peak and 0.721 and –0.625 1.386 and –1.187
hole /e·Å–3
Crystallographic data (excluding structure factors) for the structures in
this paper have been deposited with the Cambridge Crystallographic
Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK.
Copies of the data can be obtained free of charge on quoting the de-
pository numbers CCDC-1969175 (1b) and CCDC-1969176 (4a)
(Fax: +44-1223-336-033; E-Mail: deposit@ccdc.cam.ac.uk, http://
www.ccdc.cam.ac.uk)
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For biological experiments on human cancer cell lines, Dulbecco’s
Modified Eagle’s Medium (DMEM), containing 10% fetal calf serum,
1% penicillin and streptomycin, was used as growth medium. MCF-7
(breast adenocarcinoma) or HT-29 (colorectal adenocarcinoma) cells
were detached from the wells with trypsin and EDTA (0.25%), har-
vested by centrifugation and resuspended again in fresh cell culture
medium. The assays were carried out on 96 well plates with 6000
(3000) cells per well for MCF-7 (HT-29, respectively). After 24 h of
incubation at 37 °C and 10% CO2, the cells were treated with serial
dilutions of the compounds 1–4 (DMSO concentration: 0.5%) with a
final volume of 200 μL per well. For a negative control, one series of
cells was left untreated. The cells were incubated for 48 h followed
by adding 50 μL MTT (2.5 mg·mL–1). After an incubation time of 2
h, the medium was removed and 200 μL DMSO were added. The
formazan crystals were dissolved, and the absorption was measured at
550 nm, using a reference wavelength of 620 nm. Each test was re-
peated in quadruplicates in at least two independent experiments for
each cell line
Synthesis of Compounds 1–4
General Procedure: To a solution of [{M(μ-Cl)(ptpy)2}2] (M = Rh,
Ir) (0.15 mmol) in 25 mL of a mixture of CH2Cl2/MeOH/H2O (1:1:0.5)
the phenanthroline ligand (0.3 mmol) was added and the mixture re-
fluxed with stirring for 3 h. After cooling to room temperature KPF6
(0.5 mmol) was added and stirred for 20 minutes. The solvent was
removed to dryness in vacuo and the residue dissolved in dichloro-
methane and chromatographed on alumina with CH2Cl2/acetone (9:1)
as the eluent. The resulting solution was evaporated to dryness and the
residue was redissolved in 5 mL of dichloromethane or chloroform and
the product was precipitated by slow diffusion of isohexane.
[Rh(ptpy)2(5,6-dimethyl-1,10-phenanthroline)]PF6 (1a): Yield:
110 mg (46.3%). C38H32N4F6PRh: calcd. C, 57.59; H, 4.07; N, 7.07%;
found: C, 57.48; H, 4.24; N, 6.96%. MS (FAB+): m/z = 647.4 [M+]
complex cation. 1H NMR (400 MHz): δ = 8.74 (dd, J = 1.2 / 8.6 Hz,
2 H), 8.31 (dd, J = 1.2 Hz/ 4.8 Hz, 2 H), 7.88 (d, J = 8 Hz, 2 H), 7.77
(m, 4 H), 7.70 (d, J = 7.6 Hz, 2 H), 7.22 (dd, J = 1.2 / 5.4 Hz, 2 H),
6.97 (dd, J = 0.8 / 8 Hz, 2 H), 6.80 (dt, J = 1.6 / 6.4 Hz, 2 H), 6.20
(s, 2 H), 2.78 (s, 6 H), 2.13 (s, 6 H) ppm.
[Ir(ptpy)2(5,6-dimethyl-1,10-phenanthroline)]PF6 (1b): Re-
ported[11]: 1H NMR (400 MHz,): δ = 8.72 (dd, J = 2 / 12.4 Hz, 2 H),
8.27 (dd, J = 1.6/ 7.4 Hz, 2 H), 7.88 (d, J = 12 Hz, 2 H), 7.77 (m, 6
H), 7.24 (d, J = 8 Hz, 2 H), 6.94 (dd, J = 2 / 9.8 Hz, 2 H), 6.77 (dt,
J = 2/ 9.8 Hz, 2 H), 6.20 (s, 2 H), 2.84 (s, 6 H), 2.16 (s, 6 H) ppm.
[Rh(ptpy)2(2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline)]PF6
(2a): Yield: 120 mg (42.3%). C50H40N4F6PRh: calcd. C, 63.57; H,
4.27; N, 5.93 ; found: C, 63.76; H, 4.68; N, 5.64%. MS (FAB+): m/z
= 799.5 [M+] complex cation. 1H NMR (270 MHz): δ = 7.96 (s, 1 H),
7.87 (m, 5 H), 7.56 (m, 18 H), 6.91 (m, 4 H), 6.05 (s, 2 H), 2.21 (s,
6 H), 2.07 (s, 6 H) ppm.
[Ir(ptpy)2(2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline)]PF6
(2b): Reported[12]. 1H NMR (270 MHz): δ = 8.00 (s, 1 H), 7.85 (m,
5 H), 7.59 (m, 18 H), 6.86 (m, 4 H), 5.98 (s, 2 H), 2.17 (s, 6 H), 2.07
(s, 6 H) ppm.
[Rh(ptpy)2(5-amino-1,10-phenanthroline)]PF6 (3a): Yield: 100 mg
(42.8 %). C36H29N5F6PRh: calcd. C, 555.47; H, 3.75; N, 8.98 %,
found: C, 55.48; H, 3.81; N, 8.80%. MS (FAB+): m/z = 634.9 [M+]
complex cation. 1H NMR (270 MHz): δ = 8.64 (dd, J = 1.2/ 8.4 Hz,,
2 H), 8.27 (dd, J = 1.2/ 4.8 Hz, 2 H), 8.23 (dd, J = 1.2/ 8.4 Hz, 2 H),
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7.99 (dd, J = 1.2/ 5 Hz, 2 H), 7.87 (m, 2 H), 7.75 (m, 2 H), 7.68 (m,
2 H), 7.54 (m, 2 H), 7.26 (m, 2 H), 7.17 (s, 1 H), 6.96 (m, 2 H), 6.82
(m, 2 H), 6.48 (d, 2 H), 5.00 (s, 2 H), 2.14 (s, 3 H), 2.13 (s, 3 H) ppm.
[Ir(ptpy)2(5-amino –1,10-phenanthroline)]PF6 (3b): Reported[13].
1H NMR (270 MHz): δ = 8.63 (dd, J = 2/ 12.8 Hz,, 2 H), 8.29 (dd, J
= 2/ 7.6 Hz, 2 H), 8.231 (dd, J = 2/ 12.4 Hz, 2 H), 7.96 (dd, J/ =
7.2 Hz, 2 H), 7.87 (d, J = 11.6, 2 H), 7.77 (m, 2 H), 7.67 (m, 4 H),
7.65 (m, 2 H), 7.28 (m, 2 H), 7.20 (s, 1 H), 6.93 (m, 2 H), 6.79 (m, 2
H), 6.19 (d, 2 H), 5.07 (s, 2 H), 2.16 (s, 3 H), 2.15 (s, 3 H). 13C{1H}
NMR (270 MHz): δ = 168.0, 167.9, 150.9, 150.5, 150.4, 150.1, 148.4
(2), 146.8, 143.7, 141.7, 141.2, 141.0, 137.8, 135.4, 133.7, 133.1,
132.7, 132.6, 132.5, 126.3, 125.5, 124.8, 124.7, 124.6, 123.7, 122.5
(2), 119.4, 119.3, 104.8, 21.6 (Me-ptpy) ppm.
[Rh(ptpy)2(pyrazino-[2.3-f]-1,10-phenanthroline)]PF6 (4a): Yield:
100 mg (40.8%). C38H28N6F6PRh: calcd. C, 55.90; H, 3.46; N,
10.29%; found: C, 55.88; H, 3.40; N, 10.31%. MS (FAB+): m/z =
671.5 [M+] complex cation. 1H NMR (400 MHz): δ = 9.73 (dd, J =
2.4/ 10.4 Hz, 2 H), 9.17 (s, 2 H), 8.46 (dd, J = 2.4/ 7.4 Hz, 2 H), 7.95
(m, 4 H), 7.75 (m, 4 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.00 (dd, J =
1.2/ 11.8 Hz, 2 H), 6.86 (dt, J = 2/ 7.4 Hz, 2 H), 6.22 (s, 2 H), 2.16
(s, 6 H) ppm.
[Ir(ptpy)2(pyrazino[2.3-f]-1,10-phenanthroline)]PF6 (4b): Yield:
110 mg (40.5%). C38H28N6F6PIr: calcd. C, 50.38; H, 3.12; N, 9.28%;
found: C, 49.93; H, 3.19; N, 9.06%. MS (FAB+): m/z = 761.5 [M+]
complex cation. 1H NMR (400 MHz): δ = 9.69 (dd, J = 2.4/ 12.2 Hz,
2 H), 9.20 (s, 2 H), 8.43 (dd, J = 2/ 7.4 Hz, 2 H), 7.94 (dd, J = 2.4/
7.4 Hz, 2 H), 7.69 (m, 4 H), 7.75 (m, 4 H), 7.37 (dd, J = 1.2/ 7.6 Hz,
2 H), 6.95 (dd, J = 1.6/ 11.6 Hz, 2 H), 6.81 (dt, J = 2.4/ 10 Hz, 2 H),
6.21 (s, 2 H), 2.18 (s, 6 H) ppm.
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